Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.
We analyzed the outcomes of 485 patients with thalassemia major (TM) or sickle cell disease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389). Compared with patients given BMT, CBT recipients were significantly younger (media...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826298310359515136 |
|---|---|
| author | Locatelli, F Kabbara, N Ruggeri, A Ghavamzadeh, A Roberts, I Li, C Bernaudin, F Vermylen, C Dalle, J Stein, J Wynn, R Cordonnier, C Pinto, F Angelucci, E Socié, G Gluckman, E Walters, M Rocha, V |
| author_facet | Locatelli, F Kabbara, N Ruggeri, A Ghavamzadeh, A Roberts, I Li, C Bernaudin, F Vermylen, C Dalle, J Stein, J Wynn, R Cordonnier, C Pinto, F Angelucci, E Socié, G Gluckman, E Walters, M Rocha, V |
| author_sort | Locatelli, F |
| collection | OXFORD |
| description | We analyzed the outcomes of 485 patients with thalassemia major (TM) or sickle cell disease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389). Compared with patients given BMT, CBT recipients were significantly younger (median age 6 vs 8 years, P = .02), and were treated more recently (median year 2001 vs 1999, P < .01). A higher proportion of patients with TM belonging to classes II-III of the Pesaro classification received BMT (44%) compared with CBT (39%, P < .01). In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66, TM; n = 30, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had extensive chronic GVHD. With a median follow-up of 70 months, the 6-year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92). The 6-year disease-free survival (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients was 92% and 90%, respectively. The cell dose infused did not influence outcome of patients given CBT. In multivariate analysis, DFS did not differ between CBT and BMT recipients. Patients with TM or SCD have excellent outcomes after both HLA-identical sibling CBT and BMT. |
| first_indexed | 2024-03-07T04:44:52Z |
| format | Journal article |
| id | oxford-uuid:d2e5ac68-79eb-4128-ba21-09c0d8f629c2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:44:52Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:d2e5ac68-79eb-4128-ba21-09c0d8f629c22022-03-27T08:07:32ZOutcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d2e5ac68-79eb-4128-ba21-09c0d8f629c2EnglishSymplectic Elements at Oxford2013Locatelli, FKabbara, NRuggeri, AGhavamzadeh, ARoberts, ILi, CBernaudin, FVermylen, CDalle, JStein, JWynn, RCordonnier, CPinto, FAngelucci, ESocié, GGluckman, EWalters, MRocha, VWe analyzed the outcomes of 485 patients with thalassemia major (TM) or sickle cell disease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389). Compared with patients given BMT, CBT recipients were significantly younger (median age 6 vs 8 years, P = .02), and were treated more recently (median year 2001 vs 1999, P < .01). A higher proportion of patients with TM belonging to classes II-III of the Pesaro classification received BMT (44%) compared with CBT (39%, P < .01). In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66, TM; n = 30, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had extensive chronic GVHD. With a median follow-up of 70 months, the 6-year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92). The 6-year disease-free survival (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients was 92% and 90%, respectively. The cell dose infused did not influence outcome of patients given CBT. In multivariate analysis, DFS did not differ between CBT and BMT recipients. Patients with TM or SCD have excellent outcomes after both HLA-identical sibling CBT and BMT. |
| spellingShingle | Locatelli, F Kabbara, N Ruggeri, A Ghavamzadeh, A Roberts, I Li, C Bernaudin, F Vermylen, C Dalle, J Stein, J Wynn, R Cordonnier, C Pinto, F Angelucci, E Socié, G Gluckman, E Walters, M Rocha, V Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title_full | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title_fullStr | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title_full_unstemmed | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title_short | Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. |
| title_sort | outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an hla identical sibling |
| work_keys_str_mv | AT locatellif outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT kabbaran outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT ruggeria outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT ghavamzadeha outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT robertsi outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT lic outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT bernaudinf outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT vermylenc outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT dallej outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT steinj outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT wynnr outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT cordonnierc outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT pintof outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT angeluccie outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT socieg outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT gluckmane outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT waltersm outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling AT rochav outcomeofpatientswithhemoglobinopathiesgiveneithercordbloodorbonemarrowtransplantationfromanhlaidenticalsibling |